×

References: 1. Backgrounder: Guardant Reveal™ liquid biopsy test. Guardant Health, Inc. Redwood City, CA. 2. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410 3. Janni W, Huober J, Braun T, et al. Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence. Poster presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; Philadelphia, PA. Accessed November 1, 2022. https://doi.org/10.1158/1538-7445.AM2022-3403 4. Nagasaka M, Uddin MH,
Al-Hallak MN, et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021;20(1):82. doi:10.1186/s12943-021-01371-1 5. Larribère L, Martens UM. Advantages and challenges of using ctDNA NGS to assess the presence of minimal residual disease (MRD) in solid tumors. Cancers (Basel). 2021;13(22):5698. doi:10.3390/cancers13225698

The platform that harnesses the power of epigenomics and enables the next era of precision oncology.

Important Note: The Guardant Reveal and Guardant 360 Response tests were developed, and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant Reveal refers to Guardant Reveal Laboratory Developed Test (LDT). This test has not been cleared or approved by the US FDA. 

×

Reference: 1. GuardantINFINITY™: Specifications Sheet. Guardant Health, Inc. Redwood City, CA. January 4, 2023.

The only tissue-free tests to detect minimal residual disease and assess molecular response to therapy.

MONITORING AND MRD DETECTION

A suite of revolutionary liquid and tissue tests to efficiently identify biomarker matched therapies.

×

References: 1. Brand Tracker: 4Q22. Guardant Health, Inc. Redwood City, CA. December 2022. 2. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. July 2021.

Important Note: The Guardant360 Tissue Next and Guardant 360 tests was developed, and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant Reveal refers to Guardant Reveal Laboratory Developed Test (LDT). This test has not been cleared or approved by the US FDA. 

TREATMENT SELECTION

×

Reference: 1. GuardantINFINITY™: Specifications Sheet. Guardant Health, Inc. Redwood City, CA. January 4, 2023.

The platform that provides epigenomic insights with cutting-edge methylation technology.1